Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fibromyalgia
Research from A.S. Chappell and co-researchers in the area of fibromyalgia published
July 8th, 2009
According to a study from the United States, "Evaluate the efficacy and safety of duloxetine at (loses Lip to 120mg once daily in patients with fibromyalgia. This was a phase 3, 60-week study, which included all 8-week open-label period followed by a 52-week, randomized, double-blind period." "Patients received duloxetine 30 mg daily for I week and duloxetine Wing daily For 7 weeks and were then randomized to receive either 60 or 120mg daily (1:2 ratio). Enrolled patients (N = 350, 95.7% female) exhibited moderate disease symptoms at Study entry (Brief Pain Inventory average pain = 6.7, Clinical Global Impression of Severity = 4.1, and Patient's Global Impression of...
Source: Immunotherapy Weekly (2009-07-08)
|
